Azenta Life Sciences, formerly GENEWIZ’s new proprietary Sanger sequencing method sequences through difficult inverted terminal repeat (ITR) regions of adeno-associated virus (AAV), to expedite screening and validation of leads for your cell and gene therapy research.
This newly-developed protocol prevents abrupt reduction in the sequencing signal at the start of the ITR hairpin and reads through the full length of the ITR region. AAV-ITR sequencing can be combined with our Primer Walking service to sequence whole AAV vectors.
Adeno-associated virus (AAV) is one of the most actively investigated gene therapy vehicles. Azenta’s robust AAV-ITR Sequencing Protocol sequences through its difficult inverted terminal repeat (ITR) regions to better support your viral vector testing and drug discovery pipeline.
While AAV is a powerful vehicle for gene delivery, unstable ITRs threaten the fidelity of rAAV genomes. Loss of ITR integrity diminishes the packaging efficiency of rAAV particles and thus viral titer. In this tech note, discover the effect of partial and full ITR deletions on AAV packaging and how to reliably identify and effectively correct them.
In this webinar, Azenta’s Dr. Eric Zhao will present our unique AAV-ITR Sanger sequencing and AAV plasmid preparation capabilities that maintain ITR integrity for downstream virus production, as well as our next generation sequencing-enabled QC of packaged rAAV vectors and host genomes using long-read and short-read sequencing technologies.
Azenta has developed a high-quality, direct Sanger sequencing method that reads through both intact and commonly mutated inverted terminal repeat (ITR) regions of adeno-associated virus (AAV). This method is an effective tool for assessing the integrity of ITRs in AAV plasmids.
The adeno-associated virus (AAV) is a powerful vehicle for gene therapy; however, working with AAV vectors can be challenging. Spontaneous mutations in the inverted terminal repeat (ITR) regions can accumulate during plasmid propagation in bacteria. Find out how our scientists have optimized the AAV plasmid preparation process to deliver 100% accurate constructs.